Introduction {#Sec1}
============

Vascular inflammation is a primary event in the pathogenesis of atherosclerosis \[[@CR1]\]. Monocytes and lymphocytes dominate in the early atheromatous plaque, and their effector molecules accelerate plaque progression. Furthermore, inflammation can elicit acute coronary syndromes. The vascular inflammatory reaction is mediated by complex interactions between the circulating leucocytes and vascular cells (e.g., endothelial cells and smooth muscle cells). Vascular cells regulate the inflammatory process through the expression of adhesion molecules, cytokines, chemokines and growth factors. In healthy blood vessels, the endothelial cells do not adhere to the cellular constituents of the blood. Some adhesive interactions between circulating leucocytes and endothelial cells are modified by the expression of cell adhesion molecules (CAMs). Various adhesion molecules have been identified on endothelial cells, including intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) \[[@CR2]\]. These molecules are up-regulated in the vascular endothelium in response to inflammatory stimuli, including pro-inflammatory cytokines, such as tumour necrosis factor-α (TNFα) and interleukin (IL)-1, which are commonly found in atherosclerotic lesions. Over-expression of ICAM-1 and VCAM-1 is a common feature of the atherosclerotic process.

Regulation of ICAM-1 and VCAM-1 expression occurs at the transcription level and is mediated, at least in part, by nuclear factor-κB (NF-κB). This transcription factor plays an important role in the development of inflammatory responses by up-regulating the expression of many inflammatory mediators \[[@CR3]\]. In non-stimulated cells, NF-κB is mostly present in association with its inhibitory molecules (IκB). Upon the stimulation of endothelial cells by inflammatory stimuli, IκB becomes phosphorylated, permitting NF-κB to translocate into the nucleus where it binds to the promoter regions of inflammatory target genes, including ICAM-1 and VCAM-1. Previous studies have indicated that this transcription factor may play an important role in the pathogenesis of atherosclerosis. It has been suggested that NF-κB is a redox-sensitive transcription factor because reactive oxygen species (ROS) may regulate its activity \[[@CR4]\].

*Aronia Melanocarpa* (also known as black chokeberry) is a shrub of the Rosaceae family and originates from North America \[[@CR5]\]. The fruits of *A. Melanocarpa* have traditionally been used in North American folk medicine. In the 20th century, the chokeberry was introduced in the Soviet Union and Eastern Europe and has been cultivated there since then mainly for the production of juice, jam, wine and natural food colourants. *Aronia Melanocarpa* fruits have a greater content of phenolic constituents than most other blackberries. These include anthocyanins, procyanidins and phenolic acids \[[@CR6], [@CR7]\].

The high content and composition of the phenolic constituents of *A. Melanocarpa* seem to be responsible for the wide range of the fruit's potential medicinal and therapeutic effects. It has been demonstrated that chokeberry extract or juice possesses anti-oxidative, anti-viral, anti-mutagenic, anti-cancer hepatoprotective, anti-inflammatory, gastroprotective or anti-diabetic activities \[[@CR5]--[@CR8]\]. Most of the beneficial activity of *A Melanocarpa* products is probably due to the high anti-oxidative activity of their polyphenols, especially anthocyanins. Aronia berries possess the highest anti-oxidant capacity among berries and other fruits investigated to date.

Chokeberry fruit derivatives can also have a beneficial effect on several risk factors for cardiovascular disease. The lipid-lowering effect of Aronia fruit juice has been demonstrated in animal and human studies \[[@CR9], [@CR10]\]. In the animal model, chokeberry anthocyanins decrease lipid peroxidation \[[@CR11]\]. Aronia products might be useful in the prevention and control of diabetes mellitus \[[@CR12]\] and in the treatment of obesity disorders \[[@CR13]\]. Moreover, chokeberry extract has been shown to reduce blood pressure in patients with metabolic syndrome \[[@CR8]\] and in patients after myocardial infarction \[[@CR14]\]. Other effects studied include enhanced reduction in levels of cardiovascular risk markers, such as oxy-LDL, CRP, IL-6, sICAM-1, sVCAM-1 or MCP-1, in patients after myocardial infarction \[[@CR14], [@CR15]\]. Anti-platelet effects \[[@CR16]\] as well as vasoactive and vasoprotective properties in porcine coronary arteries have also been observed \[[@CR17], [@CR18]\]. In vitro studies have demonstrated that the *A. Melanocarpa* fruit extract inhibits 7β-hydroxycholesterol-induced apoptosis of endothelial cells \[[@CR19]\].

In this study, we have examined the hypothesis that commercial extract from *A. Melanocarpa* fruits can inhibit the cytokine-induced endothelial adhesiveness to peripheral blood mononuclear leucocytes and the expression of adhesion molecules (ICAM-1 and VCAM-1) in endothelial cells. In addition, potential molecular mechanisms associated with such effects, including ROS production and NF-κB activation, were studied.

Materials and methods {#Sec2}
=====================

Materials {#Sec3}
---------

EBM-2 basal medium, EGM-2 Bulletkit, foetal bovine serum (FBS), Hanks' balanced salt solution (HBSS), trypsin--EDTA and trypsin neutralising solution (TNS) were obtained from LONZA (Switzerland). 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), non-enzymatic cell dissociation solution, 2′,7′-bis-2-carboxyethyl-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM), pyrrolidine dithiocarbamate (PTDC), ibuprofen and dexamethasone were provided by Sigma (St. Louis, MO, USA). Human recombinant TNFα, Phosflow Buffer I, Phosflow Perm Buffer III, phycoerythrin (PE)-labelled mouse antibody against human ICAM-1, VCAM-1, NF-κB p65 and IgG1 (isotype control) were all supplied by Becton Dickinson (San Diego, CA, USA). 2′,7′-dichlorofluorescein diacetate (DCFH-DA) was obtained from Molecular Probes and Ficoll-Paque from Pharmacia (Sweden). A commercial extract from *A. Melanocarpa* fruit (Aronox) was purchased from Agropharm SA (Poland). This extract contained approximately 53% of total polyphenols, including 23% of anthocyanins, 15% of procyanidins and 12% of phenolic acids (information supplied by the producer). Prior to use, the extract was dissolved in PBS containing 10% DMSO (10 mg/mL) and further diluted with culture medium. Dexamethasone and ibuprofen were dissolved in ethanol and stored at concentrations of 10 and 100 mmol/L, respectively. PDTC was dissolved in medium to a stock solution of 10 mmol/L. All reagents were maintained at −20 °C, and further dilutions with culture medium were prepared before use.

Cell culture and experimental conditions {#Sec4}
----------------------------------------

Human aortic endothelial cells (HAECs) were purchased from LONZA and cultured in the endothelial cell growth medium (EGM-2 Bulletkit = EBM-2 + growth supplements + 2% FBS) according to the manufacturer's instructions. Cells were maintained at 37 °C in 5% CO~2~ in a humidified atmosphere and were used for experiments between passages 3 and 4 (doubling population ≤ 10). When the HAECs reached confluence, they were rested for 5 h in EBM-2 basal medium supplemented with 10% FBS, and the cells were pretreated with the *A. Melanocarpa* extract (1, 10 or 50 μg/mL) for 2 h. The cells were then treated with TNFα (10 ng/mL) for the indicated period of time. Cell viability, as determined by trypan blue exclusion and MTT assay, were unchanged under all the experimental conditions used.

Measurement of adhesion molecule expression using flow cytometry {#Sec5}
----------------------------------------------------------------

Resting HAECs in 12-well plates were pretreated with the indicated concentrations of *A. Melanocarpa* extract for 2 h and then treated with TNFα (10 ng/mL) for 16 h. The cells were then detached from the plate surface with a non-enzymatic cell dissociation solution, centrifuged and washed in PBS containing 1% FBS and resuspended in 100 μL of the labelling buffer. Subsequently, the cells were incubated in the dark for 1 h with PE-conjugated mouse anti-human ICAM-1 and VCAM-1 antibodies. For the isotype control, cells were treated with PE-conjugated mouse anti-IgG~1~ antibody. Next, the cells were washed with PBS and analysed (10,000 cells per sample) with a FACSCalibur flow cytometer (Becton Dickinson) using CellQuest Software. After correcting for non-specific binding using the isotype control, mean fluorescence intensity was measured as an indicator of ICAM-1 and VCAM-1 surface protein expression.

Quantitative real-time RT-PCR for ICAM and VCAM mRNA analysis {#Sec6}
-------------------------------------------------------------

Resting HAECs in 6-well plates were pretreated with *A. Melanocarpa* extract (50 μg/mL) for 2 h and then treated with TNFα (10 ng/mL) for 6 h. To determine the ICAM and VCAM mRNA levels, quantitative real-time RT-PCR was performed using a LightCycler system (ABI P[rism]{.smallcaps}^®^ 7000 Sequence Detection System, Version 1.1, Applied Biosystems). Total RNA was extracted from approximately 2 × 10^6^ cells by the method of Chomczynski and Sacchi \[[@CR20]\] using the TRIzol reagent (Invitrogen) and reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). To amplify the target genes, appropriate primers were synthesised (Institute of Biochemistry and Biophysics, Poland). The sequences of the forward and reverse primers were as follows: *h*-*ICAM1F*: 5′-CTCATCCGCGTGTGTGTGTG-3′; *h*-*ICAM1R*: 5′-GGAGGCTGAGGTGGGAGGAT-3′; *h*-*VCAM1F*: 5′-TGGGAAGATGGTCGTGATCC-3′; and *h*-*VCAM1R*: 5′-GCCTGTTGGTGCTGCAAGTC-3′. The *β*-*actin* gene was used as a reference (housekeeping) gene (forward primer, ActbF: 5′-TGAAGTGTGACGTTGACATCC-3′ and reverse primer, ActbR: 5′- GCCAGAGCAGTAATCTCCTTC-3′). Reaction mixtures (20 μL) consisted of SYBR^®^ Green PCR Master Mix (Applied Biosystems), the forward and reverse primers and an aliquot of the reverse-transcribed samples (cDNA, 2 μL). Negative controls were tested in parallel. The relative mRNA levels of the studied genes were calculated by the comparative cycle threshold (C~T~) method (ABI Prism 7000 SDS Software, Version 1.1, Applied Biosystems). *β*-*actin* mRNA levels measured in the same RNA sample for the target C~T~ normalisation were used to compute the relative gene expression ratio.

Cell adhesion assay {#Sec7}
-------------------

Peripheral blood mononuclear leucocytes (PBMLs) were isolated from the blood of healthy volunteers by density gradient centrifugation with Ficoll-Paque. The isolated mononuclear cells were resuspended in a serum-free medium and labelled with 10 μmol/L of BCECF-AM for 1 h at 37 °C. Non-fluorescent BCECF-AM is lipophilic, and its methylester is cleaved intracellularly and becomes a highly charged fluorescent BCECF that is retained by viable cells. After the labelling, cells were washed twice with PBS containing 5% FBS and resuspended in the EBM-2 medium at a density of 5 × 10^5^ cells/mL. Resting HAECs in 24-well plates were pretreated with *A. Melanocarpa* extract (50 μg/mL) for 2 h and then incubated with TNFα (10 ng/mL) for 16 h. Fluorescently labelled PBMLs (2.5 × 10^5^ cells/well) were then seeded over the HAEC monolayer and incubated for 1 h at 37 °C in 5% CO~2~. After the incubation, the mononuclear cell suspension was withdrawn, and the HAECs were washed twice with PBS to remove non-adherent cells. The fluorescence intensity of each well was measured with a fluorescence multi-well reader at excitation and emission wavelengths of 485 and 530 nm, respectively.

Measurement of NF-κB p65 phosphorylation {#Sec8}
----------------------------------------

Optimal activation of NF-κB requires phosphorylation in the transactivation domain of p65. NK-κB p65 phosphorylation was determined using flow cytometry using a specific antibody that differentiates between the phosphorylated and non-phosphorylated version of a given protein, as described previously \[[@CR21]\]. Resting HAECs cultured in 6-well plates were pretreated with *A. Melanocarpa* extract (50 μg/mL) for 2 h and then incubated with TNFα (10 ng/mL) for 45 min. The cells were then detached with a non-enzymatic cell dissociation solution and fixed with Phospho Fix Buffer I for 10 min at 37 °C. To stain intracellular phospho-p65, fixed cells were washed in PBS and permeabilised with Phospho Perm Buffer III on ice for 30 min. Next, cells were resuspended in 100 μL of staining buffer (1% FBS and PBS) and stained with PE-conjugated mouse antibody directed against human phospho-p65 for 2 h at room temperature in the dark. For the isotype control, cells were treated with PE-conjugated mouse anti-IgG2b κ antibody. The cells were then washed and analysed (10,000 cells per sample) with a FACSCalibur flow cytometer (Becton Dickinson) using CellQuest Software. After correcting for non-specific binding using the isotype control, the mean fluorescence intensity was measured.

Detection of intracellular reactive oxygen species (ROS) generation {#Sec9}
-------------------------------------------------------------------

2′,7′-dichlorofluorescein diacetate (DCFH-DA) was used to estimate the intracellular generation of ROS. The dye is a non-polar compound that readily penetrates cells. Intracellular peroxides, mainly H~2~O~2~, oxidise DCFH-DA to a highly fluorescent compound (2′,7′-dichlorofluorescein (DCF)). Resting HAECs cultured in 24-well plates were pretreated with *A. Melanocarpa* extract at the indicated concentrations for 2 h and incubated with 50 μmol/L of DCFH-DA in HBSS for 50 min. Next, cells were washed twice with PBS and incubated with TNFα (10 ng/mL) for 1 h, and the plates were then read on a fluorescence plate reader at excitation and emission wavelengths of 485 and 530 nm, respectively. Data were expressed as percentages of control values (DCF fluorescence of wells without *A. Melanocarpa* extract/TNFα treatment).

Statistical analysis {#Sec10}
--------------------

Results are expressed as means ± SD from the indicated number of experiments. Comparisons were made using the Student's *t* test. Differences between the experimental groups were considered to be statistically significant at *p* \< 0.05.

Results {#Sec11}
=======

*A. Melanocarpa* fruit extract inhibits TNFα-stimulated ICAM-1 and VCAM-1 expression in HAECs as well as leucocyte adhesion {#Sec12}
---------------------------------------------------------------------------------------------------------------------------

As cell adhesion molecules on endothelial cells mediate leucocyte adhesion to the endothelium during inflammation, we investigated the effects of *A. Melanocarpa* extract on TNFα-induced ICAM-1 and VCAM-1 expression. Our flow cytometry results demonstrated that resting HAECs exhibited low levels of surface ICAM-1 and VCAM-1 (Fig. [1](#Fig1){ref-type="fig"}). As per previous studies, the treatment of HAECs with TNFα to mimic inflammatory conditions induced higher than a 10-fold increase in ICAM-1 and VCAM-1 surface expression. Pretreatment with chokeberry extract significantly suppressed the TNFα-stimulated expression of ICAM-1 and VCAM-1 in a dose-dependent manner: at 50 μg/mL, chokeberry extract reduced the levels of expression by about 35 and 45%, respectively. Treatment of HAEC with *A. Melanocarpa* extract alone had no effect on constitutively expressed levels of ICAM-1 or VCAM-1.Fig. 1Effect of *A. Melanocarpa* extract (AME) on TNFα-induced ICAM-1 (**a**) and VCAM-1 (**b**) surface expression on endothelial cells. HAECs were incubated without (control) or with the indicated concentration of AME for 2 h and then incubated with TNFα (10 ng/mL) or TNFα alone for 16 h. Next, cells were stained for ICAM-1 and VCAM-1 and analysed using flow cytometry. Data are expressed as mean fluorescence intensity corrected for non-specific binding and are shown as mean ± SD of 6 separate experiments. \*\**p* ≤ 0.01 and \**p* ≤ 0.001 as compared to TNFα-treated cells

To understand the mechanism responsible for the inhibition of ICAM-1 and VCAM-1 by *A. Melanocarpa* extract, we examined whether this extract blocks TNFα-induced ICAM-1 and VCAM-1 mRNA levels. As shown in Fig. [2](#Fig2){ref-type="fig"}, stimulation with TNFα led to a marked increase in ICAM-1 and VCAM-1 mRNA levels in HAECs. Pretreatment with 50 μg/mL chokeberry extract caused a significant decrease in ICAM-1 and VCAM-1 mRNA expression (about 57 and 60%, respectively) as compared to TNFα-treated HAECs. These results indicate that *A. Melanocarpa* fruit extract inhibits the transcription of ICAM-1 and VCAM-1 genes.Fig. 2Effects of *A Melanocarpa* extract (AME) on TNFα-induced ICAM-1 (**a**) and VCAM-1 (**b**) mRNA expression in endothelial cells. HAECs were incubated without (control) or with AME (50 μg/mL for 2 h and then incubated with TNFα (10 ng/mL) or TNFα only for 6 h. Total RNA was isolated, and the mRNA levels of ICAM-1 and VCAM-1 were analysed by quantitative real-time RT-PCR as described in "Materials and methods". The expression levels of the control gene were set to 1, and the values are normalised to *β*-*actin*. Data are expressed as a multiple of the control and are shown as mean ± SD of 7 separate experiments. \*\**p* ≤ 0.01 and \**p* ≤ 0.001 as compared to TNFα-treated cells

We checked the functional importance of the inhibitory properties of chokeberry fruit extract for the TNFα-induced expression of ICAM-1 and VCAM-1 by investigating the adhesion of freshly isolated PBMLs to HAECs. Control HAECs showed minimal binding to PBMLs, but treatment with TNFα led to an approximately fourfold increase in adhesion (Fig. [3](#Fig3){ref-type="fig"}). Pretreatment with *A. Melanocarpa* fruit extract (50 μg/mL) significantly reduced the adhesion (about 42%) of PBMLs to TNFα-stimulated HAECs.Fig. 3Effect of *A. Melanocarpa* extract (AME) on TNFα-induced adhesiveness of endothelial cells for peripheral blood mononuclear leucocytes. HAECs were incubated without (control) or with AME (50 μg/mL) for 2 h and then incubated with TNFα (10 ng/mL) or TNFα only for 16 h. Peripheral blood mononuclear leucocytes (PBMNLs) were labelled with BCECF-AM, and binding to the endothelial cells was quantified as described in "Materials and methods". **a** Photographic view of PBMNLs adhered to HAECs. (*a*) control, (*b*) TNFα and (*c*) AME + TNFα. **b** Data are summarised and plotted. Values are expressed as % of control (set at 100%) and are shown as mean ± SD of 5 separate experiments, each performed in triplicate. \**p* ≤ 0.001 as compared to TNFα-treated cells

*A. melanocarpa* fruit extract attenuates the phosphorylation of NF-κB p65 in TNFα-stimulated HAECs {#Sec13}
---------------------------------------------------------------------------------------------------

NF-κB is a potent pro-inflammatory transcription factor, and activation of NF-κB is a central event in the inflammatory response. Optimal activation of NF-κB requires the phosphorylation of p65. Therefore, to examine whether the inhibitory effect of chokeberry fruit extract on the TNFα-induced expression of adhesion molecules is mediated by this transcription factor, we measured the phosphorylation of NF-κB p65 using flow cytometry. Incubation of HAECs with TNFα for 45 min induced the phosphorylation of NF-κB p65 (Fig. [4](#Fig4){ref-type="fig"}). Pretreatment with 50 μg/mL *A. Melanocarpa* fruit extract significantly attenuated the phosphorylation of NF-κB p65 in TNFα-stimulated HAECs.Fig. 4Effect of *A. Melanocarpa* extract (AME) on TNFα-induced phosphorylation of NF-κB. HAECs were incubated without (control) or with AME (50 μg/mL) for 2 h and then incubated with TNFα (10 ng/mL) or TNFα only for 45 min. **a** Data are expressed as mean fluorescence intensity corrected for non-specific binding and are shown as mean ± SD of 8 separate experiments. \**p* ≤ 0.001 as compared to TNFα-treated cells. **b** Representative histograms of typical experiments showing the effect of AME on TNFα-stimulated phosphorylation of NF-κB (log PE fluorescence on the X-axis)

*A. Melanocarpa* fruit extract inhibits intracellular ROS production {#Sec14}
--------------------------------------------------------------------

ROS produced by various stimuli contribute to the intracellular signalling pathways associated with the inflammatory response, including NF-κB activation \[[@CR4]\]. As tested chokeberry fruit extract inhibited TNFα-induced NF-κB activation, we therefore examined the effect of *A. Melanocarpa* fruit extract on TNFα-stimulated ROS production in HAECs. As shown in Fig. [5](#Fig5){ref-type="fig"}, there was an approximately twofold increase in intracellular ROS generation upon stimulation of the HAECs with TNFα. Treatment of endothelial cells with fruit extract prior to incubation with TNFα significantly inhibited intracellular ROS generation in a dose-dependent manner. Unstimulated HAECs (no added TNFα) treated with *A. Melanocarpa* extract (50 μg/mL) showed significantly decreased DCF fluorescence, as compared to non-extract-treated controls (*p* ≤ 0.001).Fig. 5Effect of *A. Melanocarpa extract* (AME) on TNFα-induced intracellular ROS generation in endothelial cells. HAECs were incubated without (control) or with AME (50 μg/mL) for 2 h, and the cells were then loaded with DCFH DA (50 μmol/L) for 45 min and were treated with TNFα (10 ng/mL) for 1 h. The conversion of DCFH to DCF was measured as described in "Materials and methods". Values are expressed as % of control DCF fluorescence (set at 100%) and are shown as mean ± SD of 10 separate experiments. \**p* ≤ 0.001 as compared to the TNFα-treated cells; \#p ≤ 0.001 as compared to the control

Comparison between *A.Melanocarpa* fruit extract and a panel of drugs with known anti-inflammatory and/or anti-oxidant activity in inhibiting the TNF-α-stimulated expression of ICAM-1 and VCAM-1 {#Sec15}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the next step, using the same model of TNFα-stimulated HAECs, we compared the inhibitory effect of *A.Melanocarpa* extract on pro-inflammatory responses in endothelial cells with those of other drugs with well-known anti-inflammatory and/or anti-oxidant activities. As shown above, tested chokeberry extract at a concentration of 50 μg/mL reduced ICAM-1 and VCAM-1 expression by about 35 and 45%, respectively. Dexamethasone at a concentration of 100 μmol/L reduced TNFα-induced ICAM-1 and VCAM-1 only by approximately 25 and 23%, respectively (Fig. [6](#Fig6){ref-type="fig"}). Both ibuprofen and PDTC showed similar effects on VCAM-1 expression as *A. Melanocarpa* fruit extract. Ibuprofen (1 mmol/L) inhibited TNFα-induced VCAM-1 expression by approximately 51% and PDTC (100 μmol/L) by 47%. However, the effect of ibuprofen and PDTC on ICAM-1 expression was much smaller than that of tested chokeberry extract. Ibuprofen reduced TNFα-induced ICAM-1 expression by approximately 23% and PDTC by 28%.Fig. 6Comparison between *A. Melanocarpa* extract (AME) and the panel of anti-inflammatory and/or anti-oxidant drugs on the expression of ICAM-1 (**a**) and VCAM-1 (**b**) in HAECs stimulated with TNF. HAECs were pretreated with dexamethasone (Dex) (100 μmol/L), ibuprofen (Ibu)(1 mmol/L), PDTC (100 μmol/L) and AME extract (50 μg/mL) for 2 h and then incubated with TNFα (10 ng/mL) or TNFα only for 16 h. Next, the cells were stained for ICAM-1 and VCAM-1 and analysed using flow cytometry. Data are expressed as mean fluorescence intensity corrected for non-specific binding and are shown as mean ± SD of 6 separate experiments. \**p* ≤ 0.001 as compared to TNFα-treated cells

Discussion {#Sec16}
==========

Inflammation plays an important role in atherosclerosis development and progression as well as in atheromatous plaque rupture and, thus, in the onset of acute clinical complications \[[@CR1]\]. An early stage in the inflammatory process is endothelial activation, which is directly responsible for the recruitment of circulating leucocytes. This process is self-maintaining and is mediated through the cell adhesion molecules expressed on the surface of endothelial cells, including ICAM-1 and VCAM-1 \[[@CR2]\]. Pharmacological agents that display an inhibitory effect on endothelial cell activation should have anti-inflammatory activity. The tested extract was a commercially available preparation of chokeberry, which is a condensed source of polyphenols, especially anthocyanin glycosides.

In the present study, we provide new evidence that the *A. melanocarpa* extract, rich in polyphenols, can inhibit the pro-inflammatory response of endothelial cells. We found that this chokeberry extract down-regulated TNFα-induced ICAM-1 and VCAM-1 surface protein expression in a concentration-dependent manner. In addition, real-time RT-PCR analysis showed that the suppressive effect of the *A. melanocarpa* extract on the expression of surface endothelial cell adhesion molecules was correlated with their mRNA levels. Thus, it may be suggested that the observed effect of the tested extract might be due to its influence on the mechanisms regulating the transcription of the genes encoding these molecules.

One of the functional consequences of inhibiting the surface expression of adhesion molecules should be a decrease in endothelial adhesive properties for leucocytes. Indeed, in our study, we showed that preincubation of the HAECs with *A. melanocarpa* fruit extract resulted in a reduction in TNFα-stimulated increased adhesiveness for PBMLs. Because adhesion is one of the earliest steps in inflammation and atherosclerosis, leading to the subsequent migration of blood leucocytes into the sub-endothelial space, the decrease in the adhesive properties of activated endothelial cells may be an important mechanism by which *A. Melanocarpa* fruit exerts its anti-inflammatory and anti-atherogenic effects.

The NF-κB redox-sensitive transcription factor plays a key role in TNFα-induced ICAM-1 and VCAM-1 expression \[[@CR3]\]. Its role in the pathogenesis of atherosclerosis has been indicated by studies showing that its active form is present in atherosclerotic lesions \[[@CR22]\], and the intensification of immunoreactivity for active form of NF-κB is more pronounced in patients with unstable ischaemic disease as compared with its stable form \[[@CR23]\]. The optimal activation of NF-κB, allowing its binding to the appropriate promoter regions, requires phosphorylation in the transactivation domain of the p65 protein. Thus, we decided to evaluate the effects of the investigated extract on NF-κB activation by measuring the extent of p65 phosphorylation using specific antibodies that recognise only the phosphorylated form. In the present study, we found that TNFα induced higher levels of NF-κB phosphorylation that could be decreased in HAECs when pretreated with the polyphenol-rich *A. melanocarpa extract*. These results suggest that the anti-inflammatory properties of this extract in vitro are mediated, at least in part, by the inhibition of NF-κB activation.

Several studies have indicated that ROS are implicated in the activation of NF-κB. \[[@CR4]\]. It is postulated that ROS interfere with signalling pathways, which leads to phosphorylation and subsequent IκB degradation. Our study has shown that the chokeberry extract lowers the intracellular ROS production not only in cells exposed to TNFα but also in quiescent ones.

Based on the results of our study, we assume that the inhibitory effect of *A. melanocarpa* fruit extract on ICAM-1 and VCAM-1 expression and NF-κB activation may be due to anti-oxidant properties.

Finally, the inhibitory effects of *A. Melanocarpa* fruit extract were compared with those of other drugs with well-known anti-inflammatory and/or anti-oxidant activities, such as dexamethasone, ibuprofen and PDTC. Studies conducted in the same conditions demonstrated that the extent of the inhibitory effect of the tested chokeberry extract on the TNFα-induced VCAM-1 expression was similar to that of ibuprofen and PDTC. The effect of *A. Melanocarpa* extract on TNFα-stimulated ICAM expression was much greater than that observed for ibuprofen and PDTC, while dexamethasone reduced TNFα-induced ICAM-1 and VCAM-1 expression to only a minor extent despite its strong anti-inflammatory activity. The differences observed are most likely due to varying mechanisms of action. The principal mechanism of action of dexamethasone is the so-called negative regulation by glucocorticoid receptor (GR) (transrepression), which occurs via different mechanisms \[[@CR24]\]. The most intensively investigated mechanism is the ability of the GR to inhibit the activity of other transcription factors through molecular interactions known as tethering. The transcription factors to which GR is tethered include NF-κB and activator protein-1 (AP-1), another transcription factor which is activated by most agents that activate NF-κB \[[@CR25]\]. The activation of both NF-κB and AP-1 is in most cases dependent on the production of ROS \[[@CR26]\]. We observed a minor effect on the TNFα-stimulated expression of both ICAM-1 and VCAM-1 that may be caused by the fact that the drug simultaneously enhances the production of ROS in endothelial cells \[[@CR27]\]. PDTC is a known inhibitor of NF-κB activation \[[@CR28]\] and may exert its effect via binding to the superoxide anion, thus reducing the formation of H~2~O~2~, which seems to be the principal NF-κB activator \[[@CR4]\]. The inhibitory effects of PDTC on VCAM-1 expression, which were much stronger than those exerted on ICAM-1 expression, have also been observed by other authors; these effects result probably from the fact that oxidative stress--dependent NF-κB activation is crucial for the stimulation of VCAM-1 expression but is not the only factor required for ICAM-1 induction \[[@CR29], [@CR30]\]. The effect of ibuprofen was similar to that of PDTC, which is consistent with other reports \[[@CR31]\]. The available literature suggests that ibuprofen inhibits the activation of NF-κB by blocking the activity of phosphorylating kinases IκB \[[@CR32]\]. Despite a lack of direct evidence, the similar effects of ibuprofen and PDTC on TNFα-stimulated VCAM-1 expression are thought to be due to the fact that both ibuprofen and PDTC are scavengers of hydroxyl radicals \[[@CR33]\].

*A. Melanocarpa* fruit extract contains 53% polyphenols of which the majority (23%) consist of anthocyanins, mainly cyanidin-3-glucoside. There are conflicting reports in the literature regarding the effects of anthocyanins on the TNFα-stimulated expression of ICAM-1 and VCAM-1. Studies conducted by Nizamutdinov et al*.* \[[@CR34]\] demonstrated that anthocyanins from black soybean seed coats, mainly cyanidin-3-glucoside, delphinidin-3-glucoside and petunidin-3-glucoside, inhibited TNFα-induced VCAM-1 but not ICAM-1 expression. Other studies have also shown that the same anthocyanins inhibited both TNFα-induced VCAM-1 and ICAM-1 expression through an NF-κB-dependent pathway \[[@CR35]\]. *A. Melanocarpa* extract also contains 12% phenolic acids. Recent studies have shown that caffeic acid also reduces TNFα-induced ICAM-1 and VCAM-1 by inhibiting NF-κB activation \[[@CR36]\]. Despite the fact that all tested substances inhibited the activation of NF-κB, it was the tested chokeberry extract that had the greatest effect on the pro-inflammatory activation of endothelial cells.

The concentration range of the tested extract (1--50 μg/mL) was similar to that used in other studies \[[@CR16]\]. Similar concentrations have been applied for other plant extracts rich in polyphenols \[[@CR37], [@CR38]\]. The *A. melanocarpa* berry extract used in this study at 50 μg/mL contained approximately 25 μmol/L of anthocyanin glycosides and 50 μmol/L of total polyphenols. Similar concentrations were adopted in vitro studies employing single polyphenols, such as cyanidin glycoside (1--100 μmol/L) or chlorogenic acid (25--50 μmol/L) \[[@CR39], [@CR40]\]. However, it is most likely that the achievement of such levels in the blood is not possible. Early studies show that anthocyanin glycosides are absorbed from both the stomach and the small intestine without modification, and their intact forms are detected in both plasma and urine. Depending on the anthocyanin glycoside content in the consumed product, the detected serum levels ranged from 100 to 500 nmol/L \[[@CR41], [@CR42]\]. Thus, a typical dose of commercial *A. melanocarpa* fruit extract (3 tablets; 45 mg anthocyanins) would not reach the levels of the extract used in our study \[[@CR6]\]. However, no studies have been performed yet to determine the human bioavailability of anthocyanins or other components from the specific chokeberry preparation used in this study. Additionally, it should be noted that due to the time constraints of the in vitro tests, the reaction threshold is usually obtained at higher concentrations. Moreover, long-term administration of such an extract may lead to the accumulation of active compounds and, thus, to a longer-lasting exposure of cells and the possibility of obtaining the same effect at lower doses. Garcia-Alonso et al*.* \[[@CR43]\] have reported that in spite of the low concentration of anthocyanins found in plasma after the consumption of red wine extract (12 g), an increase in the anti-oxidant capacity and a decrease in circulating MCP-1 levels in the plasma were also observed.

In summary, we found that the *A. melanocarpa* extract, which is rich in polyphenols, can reduce TNFα-induced ICAM-1 and VCAM-1 protein and mRNA expression in HAECs as well as inhibit the TNFα-induced increase in mononuclear leucocyte adhesion to HAECs. *A. melanocarpa* extract also attenuated the TNFα-induced activation of NF-κB and suppressed the production of ROS in HAECs. These findings may provide new insights into understanding the molecular mechanisms underlying the beneficial effects of *A. melanocarpa* fruits on endothelial cells and imply that these berries or other products rich in anthocyanidins may have therapeutic potential in the prevention of atherosclerosis and other pathological events involving leucocyte adhesion.
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